Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker INO · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) i… NCT03491683 · Glioblastoma INO-5401, INO-9012 | INO Inovio Pharmaceuticals | Phase 1/2 | Active, not recruiting | 52 | Dec 31, 2027 | Registry ↗ |
| Sep 2, 2026 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic… NCT03502785 · Urothelial Carcinoma INO-5401, INO-9012 | INO Inovio Pharmaceuticals | Phase 1/2 | Completed | 35 | May 9, 2025 | Registry ↗ |
| Apr 14, 2026 | INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent R… NCT04398433 · Respiratory Papillomatosis INO-3107, CELLECTRA® 2000 | INO Inovio Pharmaceuticals | Phase 1/2 | Completed | 32 | Dec 15, 2022 | Registry ↗ |
| Jan 22, 2026 | Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers NCT04588428 · Middle East Respiratory Syndrome Coronavirus (MERS-CoV) INO-4700, Placebo | INO Inovio Pharmaceuticals | Phase 2 | Completed | 192 | Jan 19, 2023 | Registry ↗ |
| Oct 17, 2024 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) NCT03721978 · Cervical Dysplasia, Cervical High Grade Squamous Intraepith… VGX-3100, Matched Placebo | INO Inovio Pharmaceuticals | Phase 3 | Completed | 203 | Aug 23, 2022 | Registry ↗ |
| Dec 20, 2023 | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2… NCT04642638 · Coronavirus Infection, Severe Acute Respiratory Syndrome Co… INO-4800, CELLECTRA® 2000 | INO Inovio Pharmaceuticals | Phase 2/3 | Terminated | 1,307 | Sep 13, 2022 | Registry ↗ |
| Aug 25, 2023 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment… NCT03180684 · Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), V… VGX-3100, Imiquimod 5% Cream | INO Inovio Pharmaceuticals | Phase 2 | Completed | 33 | Jul 23, 2020 | Registry ↗ |
| Jul 27, 2023 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) NCT03185013 · Cervical Dysplasia, Cervical High Grade Squamous Intraepith… VGX-3100, Placebo | INO Inovio Pharmaceuticals | Phase 3 | Completed | 201 | Jul 8, 2020 | Registry ↗ |
| Jul 14, 2023 | VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-1… NCT03499795 · Anal Neoplasm VGX-3100, CELLECTRA™ 5PSP | INO Inovio Pharmaceuticals | Phase 2 | Completed | 23 | Jun 16, 2020 | Registry ↗ |
| Nov 21, 2022 | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Gh… NCT04093076 · Lassa Fever INO-4500, CELLECTRA™ 2000 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 220 | Oct 14, 2022 | Registry ↗ |
| Nov 17, 2022 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers NCT05430958 · Coronavirus Infection INO-4800, INO-9112 | INO Inovio Pharmaceuticals | Phase 1 | Withdrawn | 0 | Mar 2024 | Registry ↗ |
| Apr 15, 2022 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers NCT04336410 · Coronavirus Infection INO-4800, CELLECTRA® 2000 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 120 | Feb 10, 2022 | Registry ↗ |
| Mar 4, 2022 | Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carci… NCT00198328 · Head Neck Cancer Medpulser Electroporation with Bleomycin, Surgical Excision | INO Inovio Pharmaceuticals | Phase 3 | Terminated | 84 | Jun 2007 | Registry ↗ |
| Mar 4, 2022 | Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcin… NCT00198315 · Head and Neck Cancer Medpulser electroporation with Bleomycin, Tumor surgical ex… | INO Inovio Pharmaceuticals | Phase 3 | Terminated | 130 | Jun 2007 | Registry ↗ |
| Feb 21, 2021 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer NCT02172911 · Cervical Cancer INO-3112, CELLECTRA™-5P | INO Inovio Pharmaceuticals | Phase 1/2 | Completed | 10 | Sep 7, 2017 | Registry ↗ |
| Jan 22, 2021 | Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell… NCT02163057 · Head and Neck Squamous Cell Cancer INO-3112, CELLECTRA™-5P | INO Inovio Pharmaceuticals | Phase 1/2 | Completed | 22 | Jan 23, 2017 | Registry ↗ |
| Nov 23, 2020 | Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers NCT03805984 · Lassa Fever INO-4500, Placebo | INO Inovio Pharmaceuticals | Phase 1 | Completed | 60 | Oct 21, 2020 | Registry ↗ |
| Oct 15, 2019 | Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects NCT02431312 · Hepatitis B INO-1800, INO-9112 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 90 | May 22, 2018 | Registry ↗ |
| Jun 28, 2019 | Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electropor… NCT02464670 · Ebola Vaccine INO-4201, INO-4202 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 240 | May 24, 2018 | Registry ↗ |
| Nov 19, 2018 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults Wi… NCT02960594 · Breast Cancer, Lung Cancer INO-1400, INO-9012 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 93 | Nov 9, 2018 | Registry ↗ |
| Nov 16, 2018 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies NCT02241369 · Aerodigestive Precancerous Lesions and Malignancies INO-3106, INO-9012 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 3 | Sep 2018 | Registry ↗ |
| Sep 7, 2018 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neop… NCT01304524 · Cervical Intraepithelial Neoplasia VGX 3100, Placebo | INO Inovio Pharmaceuticals | Phase 2 | Completed | 167 | May 2014 | Registry ↗ |
| Aug 10, 2018 | Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously V… NCT01188850 · Human Papillomavirus (HPV) VGX-3100 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 14 | Oct 2011 | Registry ↗ |
| Dec 26, 2017 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate… NCT02514213 · Prostate Cancer 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5m… | INO Inovio Pharmaceuticals | Phase 1 | Completed | 62 | Dec 12, 2017 | Registry ↗ |
| Oct 3, 2017 | Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous… NCT00198276 · Cancer MedPulser Electroporation with bleomycin | INO Inovio Pharmaceuticals | Phase 4 | Completed | 88 | Sep 2008 | Registry ↗ |
| Oct 3, 2017 | Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer NCT00198263 · Head and Neck Cancer Medpulser Electroporation with Bleomycin | INO Inovio Pharmaceuticals | Phase 4 | Completed | 95 | Sep 2008 | Registry ↗ |
| Sep 13, 2017 | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 NCT01403155 · Healthy INO-3401 + EP | INO Inovio Pharmaceuticals | Phase 1 | Completed | 22 | Aug 2012 | Registry ↗ |
| Sep 13, 2017 | Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults NCT01142362 · Healthy VGX-3400X | INO Inovio Pharmaceuticals | Phase 1 | Completed | 32 | Nov 2011 | Registry ↗ |
| Sep 13, 2017 | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 NCT00685412 · Papillomavirus Infections VGX-3100 | INO Inovio Pharmaceuticals | Phase 1 | Completed | 18 | Jan 2011 | Registry ↗ |
29 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances